Novel exostosin‐2 missense variants in a family with autosomal recessive exostosin‐2‐related syndrome: further evidences on the phenotype

Biallelic exostosin‐2 (EXT2) pathogenic variants have been described as the cause of the Seizures‐Scoliosis‐Macrocephaly syndrome (OMIM 616682) characterized by intellectual disability, facial dysmorphisms and seizures. More recently, it has been proposed to rename this disorder with the acronym AREXT2 (autosomal recessive EXT2‐related syndrome). Here, we report the third family affected by AREXT2 syndrome, harboring compound missense variants in EXT2, p.Asp227Asn, and p.Tyr608Cys. In addition, our patients developed multiple exostoses, which were not observed in the previously described families. AREXT2 syndrome can be considered as a multiorgan Congenital Disorder of Glycosylation caused by a significant, but non‐lethal, decrease in EXT2 expression, thereby affecting the synthesis of the heparan sulfate proteoglycans, which is relevant in many physiological processes. Our finding expands the clinical and molecular spectrum of the AREXT2 syndrome and suggests a possible genotype/phenotype correlation in the development of the exostoses.

[1]  A. Mégarbané,et al.  A novel EXT2 mutation in a consanguineous family with severe developmental delay, microcephaly, seizures, feeding difficulties, and osteopenia extends the phenotypic spectrum of autosomal recessive EXT2-related syndrome (AREXT2). , 2019, European journal of medical genetics.

[2]  M. Pacifici Hereditary Multiple Exostoses: New Insights into Pathogenesis, Clinical Complications, and Potential Treatments , 2017, Current Osteoporosis Reports.

[3]  S. Grant,et al.  Assessing the general population frequency of rare coding variants in the EXT1 and EXT2 genes previously implicated in hereditary multiple exostoses. , 2016, Bone.

[4]  John F. Robinson,et al.  Old gene, new phenotype: mutations in heparan sulfate synthesis enzyme, EXT2 leads to seizure and developmental disorder, no exostoses , 2015, Journal of Medical Genetics.

[5]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[6]  D. Stellwagen,et al.  Dystroglycan mediates homeostatic synaptic plasticity at GABAergic synapses , 2014, Proceedings of the National Academy of Sciences.

[7]  Y. Yamaguchi,et al.  Autism-like socio-communicative deficits and stereotypies in mice lacking heparan sulfate , 2012, Proceedings of the National Academy of Sciences.

[8]  L. Sangiorgi,et al.  Multiple osteochondromas: mutation update and description of the multiple osteochondromas mutation database (MOdb) , 2009, Human mutation.

[9]  G. Andelfinger Genetic factors in congenital heart malformation , 2008, Clinical genetics.

[10]  M. Lovett,et al.  The EXT2 multiple exostoses gene defines a family of putative tumour suppressor genes , 1996, Nature Genetics.

[11]  S. Selleck,et al.  Order out of chaos: assembly of ligand binding sites in heparan sulfate. , 2002, Annual review of biochemistry.

[12]  Carol Dobson-Stone,et al.  Comparison of fluorescent single-strand conformation polymorphism analysis and denaturing high-performance liquid chromatography for detection of EXT1 and EXT2 mutations in hereditary multiple exostoses , 2000, European Journal of Human Genetics.